CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Guardant Health

Erika Vento-Gaudens, Director

The Rise in Outsourcing Clinical Trials

Erika Vento-Gaudens

Erika Vento-Gaudens

As a Director of Global Clinical Trial Operations at Guardant Health, Erika Vento's primary responsibilities are to drive clinical operations and program management strategy, including multi-scale FSP/RBM (RBQM) models. Erika has more than 25 years of experience working within both sponsor and contract organizations in the biopharmaceutical industry. She leads with an effective communication style that cultivates strong cross-functional team and interdisciplinary relationships, supporting (local or global) clinical trial development and execution in complicated business matrices.


What changes do you anticipate in 25 years of experience in clinical trial management?


In my years of expertise, I've observed sponsors moving more strategically toward outsourcing their services to a CRO to become more efficient and cost-effective. Earlier pharmaceutical companies tend to have in-house staff. By using CROs, sponsors can boost their flexibility by decreasing their need for full-time internal staff and expanding their access to a wider range of expert external resources. This outsourcing trend is only set to continue and steadily increase in the future. At Guardant Health, we have decided to use a hybrid strategy for our entire clinical trial. As a result, we have both internal resources and CROs available to provide study operations services.


What have contract organizations experienced in the last 12 to 18 months that has changed significantly?


The rapid migration to digital technologies due to the pandemic will last throughout the recovery. Technology enabled everyone to communicate on the same page to support clinical operations. We modified our monitoring and operational style across teams, ensuring where the data was going and how long it was being stored and checking with IT to ensure that the servers were safe and compliant with all legal requirements. One of these changes involves the increased use of video conferencing through Zoom for business meetings and communication. 


In addition, we strive to treat everyone with great courtesy and respect while using our sites and teams.


Would you like to talk about developing organizational silos?


It's important for employees to share ideas and work well together for a successful business. Organizational silos appear to me differently. It can influence how workers communicate with one another. Sometimes, certain departments don't need to know everything that's happening in other departments unless they're directly involved. For example, if a company is audited, they don't give a wrong answer to an auditor, and it prevents them from disclosing information that they might have unintentionally learned. However, there is a time and place to be in silos. It brings the right people to the table and ensures everybody can work as a team. Team-building exercises can encourage cross-departmental collaboration among employees and allows them to foster positive workplace relationship.


I believe introducing new hires to the team in a deliberate and meaningful way organizations can build a stronger, more cohesive team


What would be your single piece of advice for the upcoming professionals in this field? 


My sole piece of advice is to value your employees. I believe organizations may create a stronger, more cohesive team by introducing new hires to the team deliberately and meaningfully. It allows existing team members to learn about the new hire and what they bring to the table. More importantly, everyone should believe that their opinions matter and that they have the freedom to express themselves. The opinions of everyone can aid businesses in making quicker and better decisions.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/the-rise-in-outsourcing-clinical-trials-nwid-918.html